Related references
Note: Only part of the references are listed.Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
Antoinette R. Tan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer
Yanli Deng et al.
XENOBIOTICA (2013)
Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Moving towards dose individualization of tyrosine kinase inhibitors
Heinz-Josef Klumpen et al.
CANCER TREATMENT REVIEWS (2011)
Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
Karel Eechoute et al.
CLINICAL CANCER RESEARCH (2011)
The Role of Therapeutic Drug Monitoring in the Management of Patients With Human Immunodeficiency Virus Infection
Erina Pretorius et al.
THERAPEUTIC DRUG MONITORING (2011)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors
E. I. Heath et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacokinetic considerations as to when to use dried blood spot sampling
Gary Emmons et al.
BIOANALYSIS (2010)
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
M. Scartozzi et al.
ANNALS OF ONCOLOGY (2009)
Phase I Trial of Pazopanib in Patients with Advanced Cancer
Herbert I. Hurwitz et al.
CLINICAL CANCER RESEARCH (2009)
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry
A. Haouala et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times
Yanfeng Wang et al.
THERAPEUTIC DRUG MONITORING (2009)
Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery
W. Cacheux et al.
ANNALS OF ONCOLOGY (2008)
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
Guru Sonpavde et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor
Philip A. Harris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Jeanine M. Roodhart et al.
CURRENT CLINICAL PHARMACOLOGY (2008)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Samuel E. DePrimo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Michael R. Mancuso et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung
A Janvier et al.
CRITICAL CARE MEDICINE (2005)
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
B Li et al.
HYPERTENSION (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
